

# Pneumococcal Vaccine Market Forecast to Surge to US\$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR

*Pneumococcal Vaccine Market Forecast to Surge to US\$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR*

NEW YORK CITY, NY, UNITED STATES, January 10, 2025 /EINPresswire.com/ -- The pneumococcal vaccine market forecast for 2032 is a specialized study of the industry with a specific concentration on the global market trend analysis.

The pneumococcal vaccine market is projected to reach a value of US\$ 14.43 billion by 2032, growing at a CAGR of 6.4% from 2024 to 2032. The market is driven by the increasing prevalence of pneumococcal infections and the growing awareness of the benefits of pneumococcal vaccines. The market is also driven by the increasing number of pneumococcal vaccine trials and the growing number of pneumococcal vaccine approvals.



Pneumococcal Vaccine Market

What are the key drivers of the pneumococcal vaccine market?

Pneumococcal illness is normal in young children, but grownups have a substantial probability of grave illness and death. Pneumococcal vaccines assist safeguard against pneumococcal infections involving invasive illness. Invasive illness indicates that bacteria occupy components of the body, such as blood, that are usually liberated from germs.



Government-subsidized immunization programs are pushing the market forward”

*Polaris Market Research*

For more information, visit <https://www.polarismarketresearch.com/industry->

[analysis/pneumococcal-vaccine-market/request-for-sample?utm\\_source=Ein&utm\\_medium=Ein&utm\\_campaign=Ein&utm\\_id=01](https://www.researchandmarkets.com/analysis/pneumococcal-vaccine-market/request-for-sample?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01)

CDC endorses pneumococcal vaccination for persons dependent on their age or if they possess specific probability conditions. Pneumococcal vaccines are the foremost method to safeguard against grave pneumococcal contamination. Government initiatives highlight the growing global allegiance to confronting pneumococcal contaminations, impacting the pneumococcal vaccine market growth favorably.

Key players in the pneumococcal vaccine market include:

- GSK plc
- Pfizer Inc.
- Merck KGaA
- Serum Institute of India Pvt. Ltd.
- CSL Ltd.
- Sanofi S.A.
- Walvax Biotechnology Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd
- Johnson & Johnson
- AstraZeneca
- Novavax

are some of the leading players in the pneumococcal vaccine market.

The market is splintered. The growing funding in R&D for pneumococcal vaccines and contemporary technology influence the global market. Some of the latest developments in the market are:

- In April 2024, Merck declared outcomes from the STRIDE-10 Phase 3 trial of its exploratory V116 pneumococcal vaccine at the ESCMID Global conference in Barcelona. V116, a 21-valent vaccine, exhibited superlative immune reactions, as contrasted to PPSV23 for allocated serotypes and better outcomes for extra serotypes.
- In December 2023, Sinovac Life Science declared clinical attempts for the Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) that involves 13 serotypes amidst children of age classification 2-23 months and 3-60 months.

Effective Vaccine Distribution: The expression of several associations for vaccine dissemination is anticipated to escalate the demand for pneumococcal vaccines worldwide, causing market growth. For instance, in 2022, GAVI registered that the scope of the third dose of the pneumococcal conjugate vaccine (PCV3) surged to 70%, up from 56% in 2019-2021.

Effective Vaccine Distribution: The expression of several associations for vaccine dissemination is anticipated to escalate the demand for pneumococcal vaccines worldwide, causing market growth. For instance, in 2022, GAVI registered that the scope of the third dose of the pneumococcal conjugate vaccine (PCV3) surged to 70%, up from 56% in 2019-2021.

Growing Cases of Pneumococcal Illnesses: The rising cases of pneumococcal illnesses covering

all age categories are driving the market ahead. Growing cases of contamination involving grave conditions such as pneumonia, meningitis, and bacteremia are pushing the demand for productive, prohibitive measures. This, in turn, is having a favorable impact on pneumococcal vaccine market sales.

**Rising Favourable Government Policies:** The market is foremost propelled by government advantages and health strategies that encourage extensive vaccination. Strategies involve embracing pneumococcal vaccines into pattern immunization programs and approving them for high-probability categories such as grown-ups and young children.

□□□□□□ □□ □ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market/request-for-discount-pricing?utm\\_source=Ein&utm\\_medium=Ein&utm\\_campaign=Ein&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market/request-for-discount-pricing?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01)

□□□□□ □□□□□□ □□□□□ □□□□□□ □□□□□□?

**North America:** North America accounted for the largest pneumococcal vaccine market share. The region's robust growth is primarily due to a robust healthcare framework and an escalating aggregate of FDA consent.

**Asia Pacific:** Asia Pacific is anticipated to witness significant growth from 2024 to 2032. This can be attributed to growing funding for vaccine advancement and a speedily burgeoning population.

□□□ □□ □□□□□□ □□□□□□□□□□□□ □□□□?

**By Vaccine Type Outlook**

- Pneumococcal conjugate vaccine
- Pneumococcal polysaccharide vaccine

**By Product Outlook**

- Prevnar 13
- Synflorix
- Pneumovax23
- Others

**By End User Outlook**

- Public Sector
- Private Sector

**By Regional Outlook**

- North America
  - o US
  - o Canada

- Europe
  - o Germany
  - o France
  - o UK
  - o Italy
  - o Spain
  - o Netherlands
  - o Russia
  - o Rest of Europe

- Asia Pacific
  - o China
  - o Japan
  - o India
  - o Malaysia
  - o South Korea
  - o Indonesia
  - o Australia
  - o Rest of Asia Pacific

- Middle East & Africa
  - o Saudi Arabia
  - o UAE
  - o Israel
  - o South Africa
  - o Rest of the Middle East & Africa

- Latin America
  - o Mexico
  - o Brazil
  - o Argentina
  - o Rest of Latin America

□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market/inquire-before-buying?utm\\_source=Ein&utm\\_medium=Ein&utm\\_campaign=Ein&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market/inquire-before-buying?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01)

□□□□:

How much is the pneumococcal vaccine market?

The market size was valued at USD 8.27 billion in 2023 and is projected to grow to USD 14.43 billion by 2032.

Which region held the highest share in the pneumococcal vaccine market?

North America held the largest share.

Which segment by type analysis had the highest revenue share in the market?

The pneumococcal polysaccharide vaccine (PPV) segment had the largest revenue share in the market.

What is the growth rate of the market?

The global market is projected to grow at a CAGR of 6.4% during the forecast period, 2024-2032.

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□:

Amyloidosis Treatment Market:

<https://www.polarismarketresearch.com/industry-analysis/amyloidosis-treatment-market>

Spatial Proteomics Market:

<https://www.polarismarketresearch.com/industry-analysis/spatial-proteomics-market>

In Vitro Diagnostics Quality Control Market:

<https://www.polarismarketresearch.com/industry-analysis/in-vitro-diagnostics-quality-control-market>

GLP-1 Analogues Market:

<https://www.polarismarketresearch.com/industry-analysis/glp-1-analogues-market>

Idiopathic Pulmonary Fibrosis Treatment Market:

<https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market>

□□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□ & □□□□□□□□□□□□, □□□:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/775821000>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.